Exploring Key Insights from the PAPILLON Trial

Opinion
Video

A clinical pharmacy specialist examines treatment strategies for EGFR exon 20 insertion mutations, referencing data from the PAPILLON trial, and addresses the challenges associated with managing brain metastases in this patient population.

  1. Amivantamab (used with or without chemotherapy, depending on the treatment stage) stands out as the sole recommended treatment for EGFR exon 20 insertion mutations. Its front-line use is supported by the PAPILLON study. What was this study’s methodology?
  2. What were the key results of PAPILLON in terms of both efficacy and safety?
  3. How do you navigate treatment decisions for EGFR-mutated NSCLC patients with brain metastases, considering CNS penetration of the various EGFR-targeted therapies?
Recent Videos
Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, an expert on RSV
Cherokee Layson-Wolf, PharmD, BCACP, FAPhA, an expert on RSV
1 KOL is featured in this program
Carrie Koenigsfeld, PharmD, FAPhA, an expert on RSV vaccination
Carrie Koenigsfeld, PharmD, FAPhA, an expert on RSV vaccination
1 KOL is featured in this program
1 KOL is featured in this program
1 KOL is featured in this series.
1 KOL is featured in this series.